News & Events

New York Medical College | Touro College

In addition to the office space, laboratory services and business development provided through BioInc@NYMC, New York Medical College’s (NYMC) biotechnology incubator and New York State-designated Innovation Hot Spot, companies receive the additional support of investor events and capital access through the TruMada Management Company.

 

New York Medical College | Touro College

Three biomedical startups presented at last week’s event:

  • Novotalk: an online, on-demand, self-directed teletherapy solution, which allows those with speech impairments to learn, practice, gain and maintain comprehensible speech remotely, independently and discretely.
  • Immunity Pharma: a company dedicated to developing innovative compounds that stimulate therapeutic cell-signaling processes for the treatment of ALS and other neurodegenerative diseases.
  • Medivizor: a free, live, health information service which delivers personalized, summarized, and bottom-lined information to the patient’s inbox, so that they may be more knowledgeable about their condition and treatment options, and better able to collaborate with their healthcare provider.

“The TruMada Initiative is a great opportunity to foster collaboration between the services available at TruMada and New York Medical College and what Israeli biotechnology startups require in the areas of business development, capital formation and office and lab space,” said Lawrence Krule, the Chief Executive Officer of the TruMada Management Company LLC. “We are proud to shed light on the tremendous medical innovations coming out of Israel and bridge the gap of experience and knowledge to help these companies expand and commercialize in the U.S.”  

Following the presentations, attendees had an opportunity to express their interest in investing in each candidate. TruMada Management Company will facilitate the dialogue between investors and presenting companies. The event was the fourth in an on-going series aimed at connecting Israeli companies with the investing community.

TruMada Initiative

The TruMada Initiative, through TruMada Management Company and BioInc@NYMC , helps post-incubated Israeli biomedical startups commercialize and establish their company in the U.S. market. BioInc@NYMC is the Hudson Valley’s only biotechnology incubator offering shared resources, turn-key wet lab space, and sponsored professional services to promising, high-potential entrepreneurs and start-ups. In addition to providing best-in-class infrastructure and operational services, BioInc@NYMC assists its members in refining their business strategies, conserving capital, building strong teams, and achieving development and funding milestones.

New York Medical College

Founded in 1860, New York Medical College is one of the oldest and largest health sciences colleges in the country with nearly 1,500 students and 330 residents and clinical fellows, more than 2,600 faculty members and 23,200 living alumni. The College, which joined the Touro College and University System in 2011, is located in Westchester County, New York, and offers degrees from the School of Medicine, the Graduate School of Basic Medical Sciences, the School of Health Sciences and Practice, a School of Dental Medicine and a School of Nursing. NYMC provides a wide variety of clinical training opportunities for students, residents, and practitioners.

The Touro College and University System

Touro is a system of non-profit institutions of higher and professional education. Touro College was chartered in 1970 primarily to enrich the Jewish heritage, and to serve the larger American and global community. Approximately 18,000 students are currently enrolled in its various schools and divisions. Touro College has 29 branch campuses, locations and instructional sites in the New York area, as well as branch campuses and programs in Berlin, Jerusalem and Moscow. New York Medical College; Touro University California and its Nevada branch campus; Touro University Worldwide and its Touro College Los Angeles division; as well as Hebrew Theological College in Skokie, Ill. are separately accredited institutions within the Touro College and University System. For further information on Touro College, please go to:  http://www.touro.edu/news/.

 

Sapience Therapeutics to Present at 2019 BIO CEO & Investor Conference

February 01, 2019

HARRISON, N.Y., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, announced today that it is scheduled to present and conduct one-on-one meetings at 2019 BIO CEO & Investor Conference to be held in New York, NY on February 11th-12th. Barry Kappel, Ph.D., MBA, President and Chief Executive Officer of Sapience Therapeutics, is scheduled to present on Tuesday, February 12th at 1:15 pm EST.

About Sapience Therapeutics Sapience Therapeutics, Inc., is a privately held, preclinical biotechnology company focused on discovering and developing peptide-based therapeutics for major unmet medical needs, particularly high mortality cancers. With platform-based discovery of peptide therapeutics that disrupt protein:protein interactions, Sapience’s molecules hold potential to target intracellular interactions that are traditionally considered “undruggable targets”. Its lead compound, ST101, is a first-in-class molecule with potential applications in various solid tumors and hematologic malignancies. In 2016, Sapience Therapeutics closed its Series A financing, which was led by Eshelman Ventures and included investments from Celgene Corporation, TaiAn Technologies Corporation and Healthlink Capital. For more information on Sapience Therapeutics, please visit www.sapiencetherapeutics.com.

Forward-Looking Statements
This press release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties. These statements are based on management’s current expectations, and actual results and future events may differ materially as a result of certain factors, including, without limitation, risks related to the application of the net proceeds from the offering to Sapience’s product development objectives, our ability to obtain additional funds, and meet applicable regulatory standards and receive required regulatory approvals. These are forward-looking statements, which speak only as of the date of this press release. Sapience does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.

Contacts
Sapience Therapeutics, Inc.:
Barry Kappel
President and Chief Executive Officer
info@sapiencetherapeutics.com

Investors:
Stephanie Carrington
ICR
Stephanie.carrington@icrinc.com
(646) 277-1282

Westchester County Association Breaking News!

January 10, 2019

Westchester County Executive George Latimer announced this morning at the Westchester County Association Breakfast that he will agree to sign a 99-year lease agreement for the North 60 project.

The agreement for the county-owned land is the key to the development of a $1.2 billion biotech project on the Grasslands Reservation in Valhalla. The Westchester County Association (WCA) has been heavily advocating for and involved with the project since its inception.

 

“It is clear that the County Executive and the Board of Legislators have made economic development a priority,” WCA President and CEO William M. Mooney, Jr. said. “This project will go a long way to solidifying our region’s brand as a hub of innovation in healthcare and life sciences. The WCA has long supported the development of the North 60 as a means to bring together academia, healthcare, life sciences and technology. It will provide meaningful opportunities for economic development, innovation and collaboration. I commend John Fareri for his vision, perseverance and passion for healthcare and life sciences in our region.”

 

https://www.westchester.org/

Retia Medical Receives U.S. FDA Clearance

January 03, 2019

Retia Medical, LLC is the first client at New York Medical College’s BioInc@NYMC to obtain FDA approval for a biomedical device. Specifically, Retia Medical has obtained U.S. Food and Drug Administration (FDA) 501(k) clearance for its innovative cardiovascular monitoring system, the Argos Hemodynamic Monitor. The device ensures cardiac output (blood flow) accuracy in a non-invasive, easier to use and less costly manner. BioInc@NYMC, a New York State-designated Innovation Hot Spot, is currently incubating multiple startups at the forefront of medical innovation. Retia Medical is one of the first companies to rely on BioInc@NYMC’s collaborative environment, state-of-the-art lab equipment and academic support to develop lifesaving technology.

 

Retia Medical is a medical device company focused on advancing the quality and clinical use of hemodynamic monitoring. Their latest advancement, the Argos CO Monitor, is now available for sale in the United States and is intended for use on patients above the age of 18.

 

“We are very proud of the work that BioInc@NYMC clients are producing every single day, from innovations in telehealth to pharmaceutical development,” said Deborah Novick, director of BioInc@NYMC. “The recent advancement from Retia Medical, is a reflection on the investment we have put into biological and medical innovation in the Hudson Valley. We look forward to future successes for Retia Medical and all BioInc@NYMC clients.”

 

The unique features and key benefits of the Argos CO monitor include superior accuracy, ease of use and cost-effectiveness. The monitor, when equipped with the company’s proprietary Multi-Beat Analysis™ (MBA) Algorithm, guarantees outstanding CO monitoring performance, reliability and compatibility for enhanced hemodynamic management.

 

Launched in October 2014, BioInc@NYMC is the Hudson Valley’s only biotechnology incubator offering shared resources, turnkey wet lab space, and sponsored professional services to promising, high-potential entrepreneurs and start-ups. In addition to providing best-in-class infrastructure and operational services, BioInc@NYMC assists its members in refining their business strategies, conserving capital, building strong teams, and achieving development and funding milestones. BioInc@NYMC occupies a 10,000-square-foot wing of a 129,000-square-foot campus building.

 

Retia Medical

Retia Medical aims to advance the use of cardiac output (CO) monitoring to improve patient care by providing members of the critical care team with a more accurate, easy-to-use, and affordable hemodynamic monitor that supports confident, data-based decisions.

 

Retia brings together industry-leading expertise in physiology, signal processing, and computational algorithms to engineer innovative monitoring solutions that give clinicians up-to-the-minute data that they can rely on to make informed patient care decisions. Additionally, Retia is committed to offering more clinicians access to CO monitoring by reducing the cost and inconvenience that limit the use of traditional CO technologies to the most high-risk patients. For additional information, please visit www.retiamedical.com.

 

About the Argos Cardiac Output Monitor

Retia Medical designed the Argos Cardiac Output (CO) Monitor to provide members of the Critical Care team in the OR and ICU with a more accurate, intuitive and affordable hemodynamic monitor that supports confident, data-based patient care decision making.

 

Equipped with Retia’s proprietary MBA™ algorithm, which uses advanced signal processing to improve the model of circulation and enables accurate tracking of both fluid and pressor resuscitation, the Argos Monitor seamlessly combines accuracy, ease of use, EMR connectivity and cost-effectiveness.

 

 

New York Medical College

 

Founded in 1860, New York Medical College is one of the oldest and largest health sciences colleges in the country with nearly 1,500 students and 330 residents and clinical fellows, more than 2,600 faculty members and 23,200 living alumni. The College, which joined the Touro College and University System in 2011, is located in Westchester County, New York, and offers degrees from the School of Medicine, the Graduate School of Basic Medical Sciences, the School of Health Sciences and Practice, as well as a school of dental medicine and a school of nursing. NYMC provides a wide variety of clinical training opportunities for students, residents, and practitioners. For more information, visit www.nymc.edu.  

 

# # #

Sapience Therapeutics to Present at Biotech Showcase 2019

January 01, 2019

Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, announced today that it will present at Biotech Showcase 2019 to be held in San Francisco, CA on January 7-9, 2019. 

Barry Kappel, Ph.D., MBA, President and Chief Executive Officer of Sapience Therapeutics, is scheduled to present on Tuesday, January 8 at 1:45 p.m. PST. For more information, please visit the Company’s website at https://www.sapiencetherapeu

About Sapience Therapeutics Sapience Therapeutics, Inc., is a privately held, preclinical biotechnology company focused on discovering and developing peptide-based therapeutics for major unmet medical needs, particularly high mortality cancers. With platform-based discovery of peptide therapeutics that disrupt protein:protein interactions, Sapience’s molecules hold potential to target intracellular interactions that are traditionally considered “undruggable targets”. Its lead compound, ST101, is a first-in-class molecule with potential applications in various solid tumors and hematologic malignancies. In 2016, Sapience Therapeutics closed its Series A financing, which was led by Eshelman Ventures and included investments from Celgene Corporation, TaiAn Technologies Corporation and Healthlink Capital.

For more information on Sapience Therapeutics, please visit www.sapiencetherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements.These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties. These statements are based on management’s current expectations, and actual results and future events may differ materially as a result of certain factors, including, without limitation, risks related to the application of the net proceeds from the offering to Sapience’s product development objectives, our ability to obtain additional funds, and meet applicable regulatory standards and receive required regulatory approvals. These are forward-looking statements, which speak only as of the date of this press release. Sapience does not undertake any

obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise. tics.com/. 

Valhalla Telemedicine Firm Looks to Improve Doctor-Patient Dynamic

December 31, 2018

More than a decade ago, Dr. Samant Virk noticed that advances in technology were helping him and countless others with mundane tasks such as banking or shopping.

When Virk, a practicing neurologist, would go to work, the tools that were helping millions of people like himself with routine matters in their personal lives were nowhere to be found to assist him, his patients or his colleagues. Most of Virk’s time was spent filling out forms, dealing with insurance companies and playing phone tag instead of helping patients.

 

Virk has sought to change that. A few years ago, he established MediSprout, a service he developed using a videoconferencing system called V2MD to conduct consultations and follow-up visits with patients rather than having them go through the trouble of the office visit. Instead of the time-consuming process of traveling, sitting in the waiting room or having the visit last longer than needed, the video connections could be as quick as five or 10 minutes long.

 

Doctors can also more quickly and easily answer a few questions patients may have rather than run the high risk of missing their calls and having trouble connecting when returning their message.

 

“I can eliminate these simple visits that they’re coming into my office for and wasting their day, and I’m taking up extra time out of my practice, and addressing them much more efficiently in follow-up care,” Virk said.

 

For the patient to connect with MediSprout’s service almost any type of computer or mobile device will work. The company, which has its office at New York Medical College in Valhalla, now works with doctors from about 25 medical practices around the United States. Patients can sign up on the website, www.medisprout.com, and are charged $4 per videoconference.

 

Of course, someone’s doctor also needs to be registered for the service in order for the patient to use it. Physicians and their medical groups can sign up on the website as well. The service is free for doctors.

 

Virk said he believed most office visits can be eliminated, although the videoconferencing is more likely to help doctors who are specialists. There still needs to be office visits for initial examinations, or in the case of primary care doctors, for annual physicals.

 

However, if doctors are aware of their patients’ stories and situation, the tasks of monitoring and answering questions can be done remotely.

 

“Our goal is to create a world where most of the visits that a doctor can perform can be virtual,” Virk said. “It’s a matter of connecting the doctor to that information so that they can do more and more of your visits virtually, and I think as we integrate technology, I want to get to a point where I can do 80, 90 percent of visits virtually.”

 

Virk said there has been some reluctance on the part of the medical community to make use of MediSprout, but that is beginning to change as doctors start understanding its advantages and realizing that the telehealth market is the wave of the future. Furthermore, in health care, patients can drive change by letting their doctors know that they want to use a service that allows them to more easily stay in contact with their physician between visits.

For the doctors, it will also reduce the amount of time they spend documenting. A recent study found that doctors spend only about 27 percent of their time with patients. For many, a large chunk of a visit is spent with the doctor’s back to the patient inputting data.

In many states, insurance companies cover videoconferencing with patients, but not phone calls.

But for Virk it’s about serving the needs of the public more effectively.

“To me, I’m not doing enough to help my patients now,” Virk said. “I want to spend my time helping my patients and this is something that I want them to know that can create a radical difference while we are able to use our knowledge to make a greater impact on people. It’s an amazing, amazing tool that we can use and we should try to embrace it, so I think we’re starting to see people understand it.”

 

For more information about MediSprout, visit www.medisprout.com

Retia Medical Establishes World-Class Clinical Advisory Board to Support Critical Advances in Hemodynamic Monitoring

October 10, 2018

Valhalla, NY – October 10, 2018 – Retia Medical, LLC, a medical device company focused on transforming the practice of critical care by making accurate hemodynamic data available and affordable for use at every bed, today announced that it established a Clinical Advisory Board comprising experts in the fields of anesthesiology and critical care medicine. The Clinical Advisory Board will provide insights into the design of clinical trials for the company’s lead product, the Retia Argos Cardiac Output Monitor, development of additional algorithms to improve hemodynamic monitoring, and support peer-to-peer educational initiatives that increase patient access to potentially life-saving hemodynamic monitoring technologies. The company also announced that it will preview the Argos Monitor at ANESTHESIOLOGY® 2018, the annual meeting of the American Society of Anesthesiology, which is taking place in San Francisco, October 13 -17

“Retia Medical was founded to address a real unmet clinical need for accurate and affordable hemodynamic data, and insights from the clinicians who use these monitors are critical components of our approach to innovation,” said Marc Zemel, S.M., M.B.A., co-founder and Chief Executive Officer of Retia Medical. “The members of our Clinical Advisory Board have already made substantive contributions to the development of the Argos Monitor and we look forward to working with them as we continue to develop novel algorithms that improve the accuracy of hemodynamic monitoring technologies.”
The members of the Retia Medical Clinical Advisory Board are:


Benjamin A Kohl, M.D., FCCM - Dr. Kohl is Chief of Critical Care Services at Jefferson Northeast and Vice Chairman of Critical Care and Chief, Division of Critical Care in the Department of Anesthesiology at Thomas Jefferson University Hospital. He is Chair of the Acute Care Medicine Committee at Aria-Jefferson Hospital and is a member of multiple committees at Aria-Jefferson Hospital and Thomas Jefferson University. Dr. Kohl currently serves on the Board of Directors of the Society of Critical Care Anesthesiology and as a reviewer for Critical Care Medicine and Chest. He was the 2009 – 2012 recipient of the Presidential Citation Award from the Society of Critical Care Medicine.


Roger Mecca, M.D. - Dr. Mecca is a Clinical Professor of Anesthesiology at University of California, Irvine, and has extensive expertise in critical care medicine, physiology, and perioperative care. He previously served as Vice President, Medical Affairs at Covidien Respiratory and Monitoring Solutions. Before that, he was Chairman, Department of Anesthesiology and Executive Director of Surgical Services at Danbury Health Systems. Dr. Mecca received his M.D. from New York Medical College and completed a residency in anesthesiology and a fellowship in critical care at Harvard Medical School. He also serves as Retia Medical’s Consultative Medical Officer.

Timothy E. Miller, M.D., CHB, FRCA - Dr. Miller is an Associate Professor of Anesthesiology, Chief of the Division of General, Vascular and Transplant Anesthesia, and Director of the Perioperative Medicine Fellowship at Duke University Hospital. His clinical and research interests are Enhanced Recovery and Perioperative Medicine, with particular interests in fluid management, and perioperative optimization of high-risk non-cardiac surgery. Dr. Miller is an associate editor for Anesthesiology and Analgesia and Perioperative Medicine, a board member of the Perioperative Quality Initiative (POQI), and a founding member and President-Elect of the American Society for Enhanced Recovery.


Michael O’Connor, M.D. - Dr. O’Connor is an anesthesiologist intensivist at the University of Chicago. He is the section head of Critical Care Medicine in the Department of Anesthesia and the Director of Critical Care Medicine at the University of Chicago Medical Center. His practice in the intensive care unit (ICU) has included the Burn ICU, Surgical ICU, Medical ICU, and Cardiothoracic ICU. He has a longstanding interest in the physiology of the circulation and the evaluation of unstable patients. He has a wide range of clinical research interests that have spanned both the operating room and the ICU.


Retia Medical’s lead product, the Argos Cardiac Output Monitor, is highly accurate, easy-to-use and cost-effective. It is equipped with the company’s proprietary Multi-Beat Analysis™ (MBA™) Algorithm, which guarantees superior CO monitoring performance, quality, reliability, and compatibility for enhanced hemodynamic management. Attendees at ANESTHESIOLOGY® 2018 can see a demonstration of the Argos Monitor and meet the company’s management at booth #1139.
About the Argos Cardiac Output Monitor


Retia Medical designed the Argos Cardiac Output (CO) Monitor to provide members of the Critical Care team in the operating room and intensive care unit with a more accurate, intuitive and affordable hemodynamic monitor that supports confident, data-based patient care decision making.
Equipped with Retia’s proprietary MBA™ algorithm, which uses advanced signal processing to improve the model of circulation and enables accurate tracking of both fluid and pressor resuscitation, the Argos Monitor seamlessly combines accuracy, ease of use, EMR connectivity and cost-effectiveness.
About Retia Medial


Retia Medical aims to advance the use of CO monitoring to improve patient care by providing members of the critical care team with a more accurate, easy-to-use, and affordable hemodynamic monitor that supports confident, data-based decisions.
Retia brings together industry-leading expertise in physiology, signal processing, and computational algorithms to engineer innovative monitoring solutions that give clinicians up-to-the-minute data that they can rely on to make informed patient care decisions. Additionally, Retia is committed to offering more clinicians access to CO monitoring by reducing the cost and inconvenience that limit the use of traditional CO
technologies to the most high-risk patients. For additional information, please visit www.retiamedical.com.

Contacts:

Corporate Contact
Jayne Peister
(914) 594-1986
jpeister@retiamedical.com
Media Contact
Erich Sandoval
(917) 497-2867
esandoval@lazarpartners.com

BCW MEMBER MEDISPROUT LAUNCHES INTEGRATED TELEHEALTH PLATFORM

October 05, 2018

MediSprout, a leader in the development of innovative healthcare and telehealth solutions, this week announced that its simple-to-implement V2MD telehealth platform will now integrate with Amazon Alexa for patient scheduling and integration with its Withings Wireless Blood Pressure Monitor. 

Click here to learn about how MediSprout launched an intergrated health platfrom 

BIOINC@NYMC WELCOMES AFFINA BIOTECHNOLOGIES AS NEWEST CLIENT

September 13, 2018

Valhalla, N.Y. – September 12, 2018New York Medical College (NYMC) announced that Affina Biotechnologies  is the latest client to join BioInc@NYMC, NYMC’s biotechnology incubator — a New York State-designated Innovation Hot Spot. Affina Biotechnologies is a drug discovery start up that also offers services in protein biochemistry and assay development. There are currently nine start-ups occupying BioInc@NYMC, the mid-Hudson Valley’s only fully-equipped incubator on a health sciences college campus.

BIOINC@NYMC WELCOMES AFFINA BIOTECHNOLOGIES AS NEWEST CLIENT

 

Drug Discovery Start-up Has Joined the Expanding Innovative Community at the Biotechnology Incubator

 

Valhalla, N.Y. – September 12, 2018New York Medical College (NYMC) announced that Affina Biotechnologies  is the latest client to join BioInc@NYMC, NYMC’s biotechnology incubator — a New York State-designated Innovation Hot Spot. Affina Biotechnologies is a drug discovery start up that also offers services in protein biochemistry and assay development. There are currently nine start-ups occupying BioInc@NYMC, the mid-Hudson Valley’s only fully-equipped incubator on a health sciences college campus.

 

“We are excited to be a part of BioInc@NYMC’s novel drug development community, and hope that our residence here will be of benefit to the other members of the incubator,” said Alexander Vinitsky, Ph.D., president and CSO, Affina Biotechnologies, Inc.

 

Affina’s drug discovery efforts are based on a proprietary, in silico screening algorithm that allows them to identify small molecule hyper-interaction modulators (SHIM®) of biomolecular complexes. These small molecules increase the stability of the targeted complexes. They have developed several chemotypes of SHIMs against tumor suppressor p53—effective against drug resistant primary ovarian cancer cells—for the treatment of ovarian, prostate, lung and blood cancers. The company is also developing SHIMs that are effective in lowering cholesterol by having a novel activity against a major cholesterol lowering target, PCSK9.

 

In addition to drug discovery work, Affina helps customers develop measurements of activities, kinetics and affinities of interactions and concentrations of biomolecules. They offer a unique mix of label-free and label-dependent assay technologies supported by scientific and technical expertise and a wide range of instrumentation.

 

“The growing list of start-ups eager to join BioInc@NYMC reflects our ability to establish ourselves as the premier biomedical incubator in the region,” said Deborah Novick, director of BioInc@NYMC. “We are committed to supporting biomedical start-ups who can benefit from our advanced equipment and resources needed to spark innovation, and are eager to see how Affina Biotechnologies will flourish while here.”

 

Launched in October 2014, BioInc@NYMC is the Hudson Valley’s only biotechnology incubator offering shared resources, turnkey wet lab space, and sponsored professional services to promising, high-potential entrepreneurs and start-ups. In addition to providing best-in-class infrastructure and operational services, BioInc@NYMC assists its members in refining their business strategies, conserving capital, building strong teams, and achieving development and funding milestones. BioInc@NYMC occupies a 10,000-square-foot wing of a 129,000-square-foot campus building.

 

New York Medical College

 

 

Founded in 1860, New York Medical College is one of the oldest and largest health sciences colleges in the country with nearly 1,500 students and 330 residents and clinical fellows, more than 2,600 faculty members and 23,200 living alumni. The College, which joined the Touro College and University System in 2011, is located in Westchester County, New York, and offers degrees from the School of Medicine, the Graduate School of Basic Medical Sciences, the School of Health Sciences and Practice, a School of Dental Medicine and a School of Nursing. NYMC provides a wide variety of clinical training opportunities for students, residents, and practitioners. For more information, visit www.nymc.edu.  

 

Affina Biotechnologies

 

Affina Biotechnologies is driven to discover novel drugs for difficult targets and are dedicated to our services in biomolecule characterization.  We bring to our work expertise in drug discovery and protein biochemistry that has been developed over many years of work in life science industry and academia.  Please visit our website at www.affinabio.com to see our offerings in services and come and talk to us about our drug discovery efforts.

MediSprout app offers timely care without waiting room angst

August 05, 2018

In 2014, Samant Virk was more than a decade into a career in private practice as a neurologist in Poughkeepsie, but he couldn’t shake the feeling that something

At his shared office space at New York Medical College’s biotech incubator in Valhalla on July 31, Virk detailed the frustrations that led him to give up a career in medicine to launch his own tech startup, MediSprout. Over four years, his company has developed a platform for virtual doctor video visits it is now marketing to medical practices.

Read the full article on Samant Virk and Medisprout.

Sapience Therapeutics, Inc. Selected as a Winner of the JLABS NYC QuickFire Challenge

June 26, 2018

HARRISON, N.Y., June 26, 2018 (GLOBE NEWSWIRE) -- Sapience Therapeutics, Inc., a biotechnology company focused on developing peptide therapeutics to address difficult to treat oncology indications, announced today that it was selected by Johnson & Johnson Innovation, JLABS (JLABS) as a winner of the JLABS @ NYC QuickFire challenge. Sapience was awarded one year of residency at the JLABS @ NYC, which includes laboratory space and access to Johnson & Johnson Innovation’s network of experts.

The JLABS QuickFire Challenges are contests designed to attract game-changing, earlystage innovation in the pharmaceutical, medical device, consumer and health tech sectors. With a platform capable of discovering peptides that disrupt protein-protein interactions (PPIs), Sapience is building a pipeline of innovative cancer treatments targeting previously “undruggable” targets that reside within the cancer cell. Sapience’s molecules target PPIs responsible for transcriptional regulation of oncogenic and immunemodulatory proteins. Sapience’s lead program, ST101, based on intellectual property licensed from Columbia University, inhibits ATF5-driven transcription and drives cancer cells toward cell death. Additional programs currently being developed via internal R&D efforts and in collaboration with the University of Bath (U.K.), target the cJun/cFos AP1 complex, undisclosed targets in the WNT pathway, and undisclosed immune-modulatory targets.

“We are very excited to join the community of QuickFire Challenge winners. At Sapience, we strive to change outcomes for patients with high mortality cancers. We have a vision of developing molecules that combine the best properties of traditional chemical-based drugs and newer biologic-based drugs, providing opportunities to hit therapeutic targets that these other classes of molecules cannot,” said Dr. Barry Kappel, founder and chief executive officer of Sapience Therapeutics. “We greatly appreciate this recognition of our innovative efforts. The network and resources available to us will be valuable as we continue to build out a broad pipeline of peptide-based therapeutics and drive towards the clinic.”

JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.

About Sapience Therapeutics
Sapience Therapeutics, Inc., is a privately held, preclinical biotechnology company focused on developing peptide-based therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our lead compound, ST101, is a first-in-class molecule with potential applications in various solid tumors and hematologic malignancies. In 2016, Sapience Therapeutics closed its Series A financing, which was led by Eshelman Ventures and included investments from Celgene Corporation, TaiAn Technologies Corporation and Healthlink Capital. For more information on Sapience Therapeutics, please visit www.sapiencetherapeutics.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties. These statements are based on management’s current expectations, and actual results and future events may differ materially as a result of certain factors, including, without limitation, risks related to the application of the net proceeds from the offering to Sapience’s product development objectives, our ability to obtain additional funds, and meet applicable regulatory standards and receive required regulatory approvals. These are forward-looking statements, which speak only as of the date of this press release. Sapience does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.

Contacts
Sapience Therapeutics, Inc.:
Barry Kappel
President and Chief Executive Officer
info@sapiencetherapeutics.com
Source: Sapience Therapeutics, Inc.

BioInc@NYMC and iCANny Host “Their Big Idea” Event

July 06, 2018

“This event is a part of our mission to foster entrepreneurship and economic growth in New York State,” said Deborah Novick, director of BioInc@NYMC.

Valhalla, NY, – On June 28, BioInc@NYMC and The Incubation, Commercialization and Acceleration Network of New York (iCANny) invited a select group of entrepreneurs to present their business ideas to expert panelists and a mixed audience of fellow entrepreneurs, financial representatives, and local business executives, who evaluated each startup concept, and provided feedback to the presenters.

Prominent strategist, Dan Potocki, founder of the business consultancy firm Finis Ventures, who gained distinction for his role in spearheading business development and strategic initiatives for tech startups, moderated the group of presenters who believe their business ventures could be the next big thing.

The presenting companies and principals included: 

  • Cara Cesario, chief scientific officer of Crave Crush: Creator of a science-backed lozenge that suppresses sugar cravings, based at BioInc@NYMC.
  • Jesse Cruz, president and CEO of Cruz Street Media: Helps organizations unlock the power of their data to drive growth by treating information as an asset and creating systems to support that data.
  • Preston Bloss, co-founder and CEO of VOLTA Reserve Power: A commercial distribution leader in advanced battery system design and consultation, delivering scalable platform solutions for renewable energy and green building applications.

 “This event is a part of our mission to foster entrepreneurship and economic growth in New York State,” said Deborah Novick, director of BioInc@NYMC. “‘Their Big Idea’ brought together a diverse mix of companies for a constructive conversation about each idea. We hope that the advice dispensed at the event will not only contribute to the future of each presenting company, but will inspire everyone who attended.”

Four panelists with a history of advising and developing startups asked questions and provided feedback on each entrepreneur’s big idea. The panelists included:

  • Scott Brenner: A veteran lawyer with more than two decades of diverse experience representing domestic and foreign businesses  ranging in development from early and emerging growth stages, to mid-market and multi-national corporations.
  • Tom Morton: Partner at TechCXO, a professional services firm that provides experienced tech company CFOs on an as-needed basis to technology companies from start-up through mid-market.
  • Hugh Schwartz: Managing director at Strategic Concepts Consulting, a firm designed to help small- and medium-sized companies get to the next level of sales and profitability by leveraging a network of former senior executives who have successfully built sustainable companies across industries and markets.
  • Wendy Wollner: Founder and CEO of Balancing Life’s Issues (BLI). With more than 25 years of experience, she has built and overseen a network of more than 1,500 BLI trainers who bring work/life balance programs to corporations, not-for-profit organizations, employee assistance programs, and educational institutions.

BioInc@NYMC is New York Medical College’s (NYMC) biotechnology incubator and the mid-Hudson Valley’s only fully-equipped biotechnology incubator on a health sciences college campus. The incubator is currently home to eight biomedical startups. iCANny is the oldest continuously operating business and technology incubator and serves as the Mid-Hudson Region’s Empire State Certified Business Incubator.  Since 2005, iCANny has been supportive of both start-ups and mature enterprises, by providing expert mentoring and advisory services as well as a curriculum to commercialization.  iCANny and NYMC first partnered in 2014 in a successful CFA submission to become the Innovation Hot Spot for the Mid-Hudson Region.

“New York is full of ambitious innovators and big ideas, but many aspiring entrepreneurs need the support of experienced executives, mentors and industry specialists in order to bring their ideas to the next level,” said Les Neumann, managing director of iCANny. “Providing guidance and support is an important part of the work we and BioInc@NYMC are doing.”

BioInc@NYMC offers shared resources, turnkey wet lab space, and sponsored professional services to promising, high-potential entrepreneurs and start-ups. In addition to providing best-in-class infrastructure and operational services, BioInc@NYMC assists its members in refining their business strategies, conserving capital, building strong teams, and achieving business development and funding milestones.

Photos from “Their Big Idea” can be found here.

New York Medical College

Founded in 1860, NYMC is one of the oldest and largest health sciences colleges in the country with more than 1,400 students, 1,300 residents and clinical fellows, nearly 3,000 faculty members, and 19,000 living alumni. The College, which joined the Touro College and University System in 2011, is located in Westchester County, New York, and offers degrees from the School of Medicine, the Graduate School of Basic Medical Sciences, the School of Health Sciences and Practice, a School of Dental Medicine and a School of Nursing. NYMC provides a wide variety of clinical training opportunities for students, residents, and practitioners.

President of Guatemala Visited NYMC To Explore Possible Collaborations

February 13, 2018

Inspired by the NYMC’s innovation around biotechnology and state-of-the-art medical equipment, President Morales plans to take key learning points back to people of Guatemala.

Valhalla, N.Y. – February 13, 2018 - On Friday, February 9, President Jimmy Morales of Guatemala visited the campus of New York Medical College (NYMC) to tour the school’s biotechnology incubator, the medical simulation facility and the new dental school, Touro College of Dental Medicine. As part of the visit, President Morales discussed a future collaboration between Guatemala and NYMC and praised the school’s incubator program, BioInc@NYMC, as a model for helping startups and inventors break into the biotechnology industry.

President Morales was joined by senior advisors including Minister of Foreign Affairs- Sandra Jovel Polanco, Minister of Defense- Luis Miguel Romero, Minister of Interior - Enrique Antonio Degenhart Asturias, Minister of Economy- Acisclo Valladares Urruela, Minister of Strategic Intelligence - Mario Duarte, Secretary of Political Affairs - Andres Castro, and Guatemala’s Ambassador to the U.S. - Manuel Espina.

After the tour, President Morales said, “New York Medical College’s use of health care simulators could show Guatemala how to provide better care of children and more effective first aid.” He also spoke about the possibility of integrating the technology and services available at NYMC to improve medical care in Guatemala.  

“We were honored to host President Morales and see multiple opportunities for collaboration with Guatemala,” said  Edward C. Halperin, M.D., M.A., chancellor and chief executive officer of NYMC. “This collaboration could include supporting the growing biotechnology market in Latin America, developing the clinical trial sector in Guatemala, or helping to fight the burden of dental disease.”

“Global collaboration—coming together to share ideas across our distinct milieus—makes us all better healthcare providers,” said Gladys Ayala, M.D., M.P.H., interim vice dean of the NYMC School of Medicine. “We have an exciting opportunity to learn from and teach one another across the globe.”

President Morales and NYMC will continue a conversation around how they can best work together in the future.

View the Visit by the President of Guatamala's photo album; video available upon request. 

New York Medical College

Founded in 1860, NYMC is one of the oldest and largest health sciences colleges in the country with more than 1,400 students, 1,300 residents and clinical fellows, nearly 3,000 faculty members, and 19,000 living alumni. The College, which joined the Touro College and University System in 2011, is located in Westchester County, New York, and offers degrees from the School of Medicine, the Graduate School of Basic Medical Sciences, the School of Health Sciences and Practice, a School of Dental Medicine and a School of Nursing. NYMC provides a wide variety of clinical training opportunities for students, residents, and practitioners.

TruMada Initiative Hosts Entrepreneurs And Prospective Investors For "Shark Tank" Inspired Event

February 08, 2018

We are seeing tremendous medical innovation come out of Israel, but many of these companies lack the knowledge and experience to successfully expand in the U.S.

Valhalla, NY – February 8, 2018 – On Tuesday, January 30th, the Touro College and University System’s TruMada Initiative held an investor event inspired by the hit TV show “Shark Tank.” Select Israeli startups had the opportunity to pitch their solutions to an exclusive group of invited U.S. investors who have shown interest in helping Touro and New York Medical College expand their presence in biomedical research. The TruMada Initiative helps post-incubated Israeli biomedical startups establish their companies in the U.S. market and helps them commercialize their unique offerings. In addition to the business development and laboratory services provided through BioInc@NYMC, companies receive the additional support of investor events and capital access through the TruMada Management Company.

Three biomedical startups presented at last week’s event:

  • POP Medical Solutions: developer of the NeuGuide, a FDA-cleared, minimally-invasive surgical system for treating Pelvic Organ Prolapse (POP), a condition that affects 3 out of 10 women.
  • Magenta Medical: clinical-stage company dedicated to catheter-based solutions for the treatment of Acute Heart Failure. Its products include a temporary axial-flow pump placed in the renal veins of hospital-admitted patients with Acute Decompensated Heart Failure (ADHF) and a percutaneous left ventricular assist device (pLVAD), a temporary catheter placed in the left ventricle of an acutely failing heart to provide mechanical support for several days to weeks.
  • ViruCure Therapeutics: developing a novel biological pharmaceutical platform for targeted treatment of a wide range of cancers based on proprietary strains of the Newcastle Disease Virus (NDV), an oncolytic virus.  

Following the presentations, attendees expressed interest in investing in each startup. TruMada Management Company will facilitate the dialogue between investors and presenting companies. The event was the first in an on-going series aimed at connecting Israeli candidate companies with the investing community.

“With access to business development services, scientists with FDA experience and lab space, we think there is tremendous synergy between services available at New York Medical College and what biotechnology startups require,” said Dr. Alan Kadish, president of the Touro College and University System. “Fostering this collaboration allows the facilitation of scientific research, nurtures a growing community of scientists and will help companies catalyze science into clinical and commercial development.  Combined with the support of the TruMada Investor Club, all of this will hopefully translate into a higher degree of success compared to companies that try to go it alone.”

“Touro/NYMC wishes to enhance its reputation as an innovative, prominent healthcare research institution, and attracting cutting-edge, Israeli biotech companies to its NYMC campus is one part of a plan to do that,” said David Raab, Executive Vice President of Touro College and University System. “As those companies succeed, we hope that their reputational and financial success will accrue in part to Touro, NYMC, and BioInc.”

“We had significant interest expressed in the three companies by the potential investors who attended the shark tank. We are following up with them and believe that at least one financing deal will be forthcoming,” said Lawrence Krule, CEO of TruMada Management Company, LLC. “This shark tank was the first in an ongoing series and we will continue to host and provide additional opportunities for investors to meet with leading companies coming out of Israeli’s startup community.”

"The three companies that presented reflect some of the great innovations happening in the Israeli healthcare space," said Dr. Salomon Amar, Provost for Biomedical Research and Chief Biomedical Research Officer Touro College and University System. "With the TruMada Initiative, we will help bring these pioneering ideas to a global audience."

“We are seeing tremendous medical innovation come out of Israel, but many of these companies lack the knowledge and experience to successfully expand in the U.S. That’s the gap we are trying to bridge with the TruMada Initiative, by providing these companies with a home, with business-development services, and access to capital,” said Deborah Novick, the director of BioInc@NYMC and the TruMada Initiative.

TruMada Initiative

The TruMada Initiative, through BioInc@NYMC and the TruMada Management Company, helps post-incubated Israeli biomedical startups commercialize and establish their company in the U.S. market. BioInc@NYMC is the Hudson Valley’s only biotechnology incubator offering shared resources, turn-key wet lab space, and sponsored professional services to promising, high-potential entrepreneurs and start-ups. In addition to providing best-in-class infrastructure and operational services, BioInc@NYMC assists its members in refining their business strategies, conserving capital, building strong teams, and achieving development and funding milestones. TruMada Management Company, LLC facilitates investment in companies screened by BioInc@NYMC. 

The Touro College and University System

Touro is a system of non-profit institutions of higher and professional education. Touro College was chartered in 1970 primarily to enrich the Jewish heritage, and to serve the larger American and global community. Approximately 18,000 students are currently enrolled in its various schools and divisions. Touro College has 29 branch campuses, locations and instructional sites in the New York area, as well as branch campuses and programs in Berlin, Jerusalem and Moscow. New York Medical College; Touro University California and its Nevada branch campus; Touro University Worldwide and its Touro College Los Angeles division; as well as Hebrew Theological College in Skokie, Ill. are separately accredited institutions within the Touro College and University System. For further information on Touro College, please go to:  http://www.touro.edu/news/.

New York Medical College

Founded in 1860, New York Medical College (NYMC) is one of the oldest and largest health sciences colleges in the country with more than 1,400 students, 1,300 residents and clinical fellows, nearly 3,000 faculty members, and 16,000 living alumni. The College, which joined the Touro College and University System in 2011, is located in Westchester County, New York, and offers advanced degrees from the School of Medicine, the Graduate School of Basic Medical Sciences, and the School of Health Sciences and Practice. The College manages more than $32.6 million in research and other sponsored programs, notably in the areas of cancer, cardiovascular disease, infectious diseases, kidney disease, the neurosciences, disaster medicine, and vaccine development. With a network of affiliated hospitals that includes large urban medical centers, small suburban clinics and high-tech regional tertiary care facilities, NYMC provides a wide variety of clinical training opportunities throughout the tristate region for medical students, residents, and other health providers. 

BioInc@NYMC Names New Director

January 11, 2018

BioInc@NYMC has established itself as the premier biomedical incubator in the region and I am eager to join and help support its mission and the success of its members

Valhalla, N.Y. – New York Medical College (NYMC) today announced the appointment of Deborah Novick to Director of BioInc@NYMC — NYMC’s biotechnology incubator and New York State-designated Innovation Hot Spot. In addition to running operations for BioInc@NYMC, Ms. Novick will also be responsible for correlative aspects of the TruMada Initiative, focused on helping post-incubated Israeli biomedical start-ups through business development services and capital access.

Deborah Novick“BioInc@NYMC concluded 2017 receiving a $1.25 million grant from Empire State Development and the Mid-Hudson Regional Development Council to continue the incubator’s outstanding work promoting innovation and economic prosperity in the region,” said David Raab, Executive Vice President of Touro College and University System (TCUS). “With Ms. Novick as Director, we know the program will maintain its upward trajectory and continue to serve as a leading resource for biomedical entrepreneurs.”

“Deborah Novick’s specific skills and expertise will provide our clients with the guidance they need to strategically grow and scale their company. We are excited to welcome Ms. Novick into the New York Medical College and Touro communities,” said Edward C. Halperin, M.D., M.A., Chancellor and CEO.

Ms. Novick brings extensive experience working directly with entrepreneurs as an instructor for the Women’s Enterprise Development Center (WEDC), an organization dedicated to empowering women to build successful small businesses in Westchester County and the Hudson Valley. She has served as a consultant to startups and established entrepreneurs in the areas of strategy, growth and business development and has helped raise capital for early stage companies, in the private and public capital markets, handling transactions ranging in size from $50,000 to $20 million.

“BioInc@NYMC has established itself as the premier biomedical incubator in the region and I am eager to join and help support its mission and the success of its members,” said Deborah Novick.” My previous experience working with Westchester County startups and raising capital has prepared me to take on this prestigious position.”

As Director, Ms. Novick will be responsible for managing the operations, planning, marketing, strategic direction and development of BioInc@NYMC, working directly with candidate companies, client firms, service providers and the NYMC and Touro community.

Launched in October 2014, BioInc@NYMC is the Hudson Valley’s only biotechnology incubator offering shared resources, turnkey wet lab space, and sponsored professional services to promising, high-potential entrepreneurs and start-ups. In addition to providing best-in-class infrastructure and operational services, BioInc@NYMC assists its members in refining their business strategies, conserving capital, building strong teams, and achieving development and funding milestones. BioInc@NYMC occupies a 10,000-square-foot wing of a 129,000-square-foot campus building. 

New York Medical College 

Founded in 1860, NYMC is one of the oldest and largest health sciences colleges in the country with more than 1,400 students, 1,300 residents and clinical fellows, nearly 3,000 faculty members, and 19,000 living alumni. The College, which joined the Touro College and University System in 2011, is located in Westchester County, New York, and offers degrees from the School of Medicine, the Graduate School of Basic Medical Sciences, the School of Health Sciences and Practice, a School of Dental Medicine and a School of Nursing. NYMC provides a wide variety of clinical training opportunities for students, residents, and practitioners.

BioInc@NYMC Client Crave Crush Now Available Nationwide

August 17, 2017

Crave Crush helps individuals lead healthier lives by eating less sugar. The main ingredient in its patented lozenge is gymnema, a natural leaf extract that supports healthy dietary habits. 

VALHALLA, N.Y., August 17, 2017—BioInc@NYMC, New York Medical College’s biotechnology incubator, has announced its client, Crave Crush, has launched a new product, a mint lozenge that reduces sugar cravings within seconds, at The Vitamin Shoppe retail locations nationwide.

Crave Crush helps individuals lead healthier lives by eating less sugar. The main ingredient in its patented lozenge is gymnema, a natural leaf extract that supports healthy dietary habits. Gymnema influences the tongue's sweet taste receptors, thereby preventing activation of those receptors by sugar molecules and preventing those receptors from signaling the brain.

“We are pleased to see the success of Crave Crush and are excited that consumers around the country can now access a one-of-a-kind product that has the potential to change lives,” said Randi D. Schwartz, M.B.A., Director of BioInc@NYMC. “We will continue to invest in our BioInc@NYMC clients and watch as they develop from conception.”

Crave Crush is one of nine startup clients at BioInc@NYMC. As a member of NYMC’s incubator program, Crave Crush has access to invaluable resources, such as cutting-edge core facilities, wet lab space, shared resources, collaboration with scientists and clinicians, and sponsored professional services. As part of the program, BioInc@NYMC also assists its clients in refining their business strategy, conserving capital, building strong teams and achieving development and funding milestones.

“We are grateful for the ongoing support of BioInc and New York Medical College.  The state-of-the-art incubator facilities enabled us to accelerate our product development and own our research process,” said Arianne Perry, President & COO of Crave Crush LLC.

Launched in October 2014, BioInc@NYMC occupies a 10,000-square-foot wing of a 129,000-square-foot campus building. BioInc@NYMC has grown to more than 6,500-square-feet with finished laboratories, offices and shared infrastructure ready for immediate occupancy. Development of the remaining space is planned to proceed as the initial spaces are filled. Additional available space in the same building (50,000 to 60,000 square feet) is ideal for future growth of the incubator or related biomedical research activities.

About New York Medical College

Founded in 1860, NYMC is one of the oldest and largest health sciences colleges in the country with more than 1,400 students, 1,300 residents and clinical fellows, nearly 3,000 faculty members, and 19,000 living alumni. The College, which joined the Touro College and University System in 2011, is located in Westchester County, New York, and offers degrees from the School of Medicine, the Graduate School of Basic Medical Sciences, the School of Health Sciences and Practice, a School of Dental Medicine and a School of Nursing. NYMC provides a wide variety of clinical training opportunities for students, residents, and practitioners.

New York Medical College Welcomes Two New BioInc Tenants

November 10, 2015

SHY Therapeutics and MediSprout Join NYMC’S Innovative Biotech Incubator

Valhalla, N.Y., November 10, 2015— New York Medical College (NYMC) today welcomed two new tenants—SHY Therapeutics and MediSprout—to , Hudson Valley’s only biotechnology incubator operating with the aim of finding new ways to prevent and treat human disease and disability, a mission that is shared with the tenants the incubator currently houses and attracts.

SHY Therapeutics is involved in therapeutic product research, and MediSprout is a telehealth solution that provides medical offices with online communication tools for their patients to instantly connect with clinicians and schedule virtual visits. The two companies join BioInc@NYMC’s existing tenants, which include:

  • Four LLC—a nutrition, health and fitness consumer product company
  • MOE Medical Devices LLC—a maker of cold electrical plasma therapeutics
  • Conversion Energy Enterprises—a corporation that develops and prototypes laser products for medical applications

“BioInc@NYMC continues to thrive with the addition of SHY Therapeutics and MediSprout,” said Randi D. Schwartz, M.B.A., interim director of BioInc@NYMC and associate dean for academic administration. “The cutting-edge research generated by both companies will supplement the innovative work already taking place at the incubator. BioInc continues to generate new knowledge about biomedicine, addressing the global health research shortage while serving as an economic engine for the local community.”

“In a world full of ever-increasing online interactions, MediSprout creates a mutually beneficial outcome that offers access and convenience to patients while creating efficiency and revenue for physicians,” said Samant Virk, M.D., MediSprout founder and CEO. “It is easy to implement, cost-effective and scalable, and stands out because its connectivity is both a consumer and enterprise-facing solution. We look forward to tying into other groundbreaking technology at BioInc to open a new world of possibilities in health care delivery.”

“We are excited to join BioInc@NYMC and be part of the growing group of innovative companies already working in the incubator” said Yaron Hadari, Ph.D., co-founder and CEO of SHY Therapeutics. “We are convinced that the supportive environment in the incubator will help SHY to develop its future therapeutics products.”

A top regional economic priority from 2011 to 2013, BioInc@NYMC is a public-private enterprise, combining resources from the federal government, New York State, Westchester County and NYMC, and is the only incubator of its kind in the region that is directly co-located with a health sciences college campus. Its convenient location, with its proximity to New York City, allows NYMC to go beyond providing start-ups with affordable space, giving them access to invaluable resources, such as cutting-edge core facilities with wet lab space, shared resources, collaboration with scientists and clinicians, and sponsored professional services to promising entrepreneurs and start-ups.

Additionally, BioInc@NYMC assists members in refining business strategies, conserving capital, building strong teams and achieving development and funding milestones. It has been approved by Start-Up NY and has received the multi-year Mid-Hudson Innovation Hot Spot award granted by the New York State Regional Economic Development Council.

Launched in October 2014, BioInc@NYMC occupies a 10,000-square-foot wing of a 129,000-square-foot campus building. An initial build-out of 4,500-square-feet with finished laboratories, offices and shared infrastructure is ready for immediate occupancy. Development of the remaining space is planned to proceed as the initial spaces are filled. Additional available space in the same building (50,000 to 60,000 square feet) is ideal for future growth of the incubator or related biomedical research activities.

About New York Medical College
Founded in 1860, NYMC is one of the oldest and largest health sciences colleges in the country with more than 1,400 students, 1,300 residents and clinical fellows, nearly 3,000 faculty members, and 19,000 living alumni. The College, which joined the Touro College and University System in 2011, is located in Westchester County, New York, and offers advanced degrees from the School of Medicine, the Graduate School of Basic Medical Sciences, and the School of Health Sciences and Practice. The College manages more than $32.6 million in research and other sponsored programs, notably in the areas of cancer, cardiovascular disease, infectious diseases, kidney disease, the neurosciences, disaster medicine, and vaccine development. With a network of affiliated hospitals that includes large urban medical centers, small suburban clinics and high-tech regional tertiary care facilities, NYMC provides a wide variety of clinical training opportunities throughout the tri-state region for medical students, residents, and other health providers.

BioInc@NYMC Welcomes Sapience Therapeutics, Inc.

August 03, 2016

Sapience Therapeutics, Inc. Developing Therapeutic Agent to Address High Mortality Cancers

Valhalla, N.Y., August 3, 2016 – New York Medical College (NYMC) recently welcomed Sapience Therapeutics Inc., to BioInc@NYMC, the only biotech incubator in the region that is co-located within a health sciences college campus.

In addition to being welcomed into BioInc’s premier incubation program, Sapience Therapeutics, which is developing novel therapeutics to address high mortality cancers, recently announced that it completed a $22.5 million Series A financing. The funding will primarily support the development of Sapience’s main drug candidate, ST-36, which specifically targets a protein that promotes the growth of numerous types of tumors, including glioblastoma, the most severe and deadly form of brain cancer. For additional information visit the company’s website at www.sapiencetherapeutics.com.

"We are pleased to be part of the growing biotechnology community in Westchester County and specifically at BioInc@NYMC,” said Dr. Barry Kappel, the President and Chief Executive Officer of Sapience Therapeutics.  “The BioInc@NYMC incubator provides us with the resources to develop our novel treatment approaches and flexibility to grow as needed.  Importantly, BioInc@NYMC allows a start-up such as Sapience to hit the ground running and work towards our goal of saving patients’ lives.”

“Sapience Therapeutics is an addition to BioInc that will play an essential role in furthering our mission of exploring new treatments and applications for human disease through biomedicine,” said Randi D. Schwartz, M.B.A., interim director of BioInc@NYMC and associate dean for academic administration. “Their recent round of funding is a testament to their promise for the world of oncology and puts them one step closer to developing solutions for treating high-mortality cancers.”

“BioInc@NYMC continues to support young companies that are tackling global health issues,” said Douglas Miller M.D., C.M., M.B.A., dean of the School of Medicine at New York Medical College. “Sapience Therapeutics has licensed intellectual property from Columbia University from which the company is developing novel solutions in the field of oncology. Sapience will serve to enrich the BioInc culture that is making strides to improve the world through the use of biotechnology and medicine.”

A top regional economic priority, BioInc@NYMC is a public-private enterprise, combining resources from the federal government, New York State, Westchester County and NYMC. BioInc’s proximity to New York City goes beyond providing start-ups simply with affordable space: it gives them access to invaluable resources, such as cutting-edge core facilities with wet lab space, shared resources, collaboration with scientists and clinicians, and sponsored professional services.

Additionally, BioInc@NYMC assists members in refining business strategies, conserving capital, building strong teams and achieving development and funding milestones. It has been approved by Start-Up NY and has received the multi-year Mid-Hudson Innovation Hot Spot award granted by the New York State Regional Economic Development Council.

Launched in October 2014, BioInc@NYMC occupies a 10,000-square-foot wing of a 129,000-square-foot campus building. An initial build-out of 4,500-square-feet with finished laboratories, offices and shared infrastructure is ready for immediate occupancy. Development of the remaining space is planned to proceed as the initial spaces are filled. Additional available space in the same building (50,000 to 60,000 square feet) is ideal for future growth of the incubator or related biomedical research activities.

In addition to Sapience Therapeutics, BioInc@NYMC’s tenants include:

  • Accent BioSystems: Developing new technologies in protein production, analysis, crystallization and structure determination
  • Four LLC: Creating a new category in sustainable nutrition with products that instantly curb cravings
  • MediSprout: Providing physicians and patients with tools to instantly connect and schedule virtual visits
  • MOE Medical Devices LLC: Creating cold electrical plasma therapeutics
  • Conversion Energy Enterprises: Developing and prototyping innovative laser products for medical applications
  • SHY Therapeutics: Researching and developing therapeutic oncology products

About Sapience Therapeutics

Sapience Therapeutics, Inc., is a privately held, preclinical stage biotechnology company focused on developing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma (GBM), which is the most severe and deadly form of brain cancer.  For more information on Sapience Therapeutics, please visit www.sapiencetherapeutics.com.

About New York Medical College

Founded in 1860, NYMC is one of the oldest and largest health sciences colleges in the country with more than 1,400 students, 1,300 residents and clinical fellows, nearly 3,000 faculty members, and 16,000 living alumni. The College, which joined the Touro College and University System in 2011, is located in Westchester County, New York, and offers advanced degrees from the School of Medicine, the Graduate School of Basic Medical Sciences, and the School of Health Sciences and Practice. With a network of affiliated hospitals that includes large urban medical centers, small suburban clinics and high-tech regional tertiary care facilities, NYMC provides a wide variety of clinical training opportunities throughout the tri-state region for medical students, residents, and other health providers.

NYMC Biotechnology Incubator Receives More Than One Million Dollars in State Funding To Support Innovation Hot Spot

December 22, 2017

BioInc@NYMC has seen phenomenal growth and success in its short three-year history

Valhalla, N.Y. – December 22, 2017 – New York Medical College (NYMC) has received $1.25 million, awarded by Empire State Development (ESD) and the Mid-Hudson Regional Development Council (REDC) to support operations of BioInc@NYMC — NYMC’s biotechnology incubator and NY State-designated Innovation Hot Spot. The second largest award in the region this year, it follows earlier ESD awards in which the REDC recognized BioInc@NYMC as a regional priority.

“This investment affirms the reputation of the flourishing BioInc@NYMC program and supports our mission to spur economic growth in the Mid-Hudson region,” said David Raab, Executive Vice President of Touro College and University System (TCUS). “BioInc@NYMC will be able to continue offering entrepreneurs industry-grade equipment, space to develop their ideas, and a network of mentors to help navigate the competitive biopharmaceutical market. We thank Governor Cuomo for creating the REDC to prioritize job growth in the region and will use these funds to do just that.”  

“BioInc@NYMC is composed of some of the most talented entrepreneurs I have ever had the privilege of working with,” said Lawrence Krule, Interim Director of BioInc@NYMC. “These additional resources will help us bring even more startups into the program and continue supporting innovation and economic development in our community.”

“BioInc@NYMC has seen phenomenal growth and success in its short three-year history, and we appreciate the investment of ESD and the Mid-Hudson REDC in our vision,” said Robert W. Amler, MD, MBA, NYMC’s Vice President for Government Affairs and Dean of the School of Health Sciences and Practice. “Our diverse client firms have generated an environment of great energy and excitement, and we take much pleasure in their every success.”  

Launched in October 2014, BioInc@NYMC is the Hudson Valley’s only biotechnology incubator offering shared resources, turnkey wet lab space, and sponsored professional services to promising, high-potential entrepreneurs and start-ups. In addition to providing best-in-class infrastructure and operational services, BioInc@NYMC assists its members in refining their business strategies, conserving capital, building strong teams, and achieving development and funding milestones. BioInc@NYMC occupies a 10,000-square-foot wing of a 129,000-square-foot campus building.

BioInc@NYMC’s tenants include:

  • Accent BioSystems: Developing new technologies in protein production, analysis, crystallization and structure determination
  • Conversion Energy Enterprises: Developing and prototyping innovative laser products for medical applications
  • Four LLC: Creating a new category in sustainable nutrition with products that instantly curb cravings
  • MediSprout: Providing physicians and patients with tools to instantly connect and schedule virtual visits
  • MOE Medical Devices LLC: Creating cold electrical plasma therapeutics
  • Philips Intellispace Genomics: Developing  oncology genomics and collaborative computational genomics of large data sets
  • Sapience: Advancing novel therapeutics for major unmet medical needs
  • SHY Therapeutics: Researching and developing therapeutic oncology products

New York Medical College
Founded in 1860, NYMC is one of the oldest and largest health sciences colleges in the country with more than 1,400 students, 1,300 residents and clinical fellows, nearly 3,000 faculty members, and 19,000 living alumni. The College, which joined the Touro College and University System in 2011, is located in Westchester County, New York, and offers degrees from the School of Medicine, the Graduate School of Basic Medical Sciences, the School of Health Sciences and Practice, a School of Dental Medicine and a School of Nursing. NYMC provides a wide variety of clinical training opportunities for students, residents, and practitioners.

NYMC Welcomes New BioInc Client

April 15, 2015

Four LLC to Become Fourth Member of the College’s Innovative Biotech Incubator

Valhalla, N.Y. – April 14, 2015 – New York Medical College (NYMC) today welcomed Four LLC—a nutrition, health and fitness consumer product company—as a new client of BioInc@NYMC, the College’s biotechnology incubator. Opened in October 2014, BioInc@NYMC operates with the aim of finding new ways to prevent and treat human disease and disability, a quality that is shared with the type of clients the incubator houses and attracts.

Four LLC was founded in 2013 to research, create and market nutrition products based on life science patents. Four LLC’s products—currently under development— aim to curb food cravings, creating a new category in sustainable nutrition. The first product launch is expected in early 2016.

“Four LLC is a welcome addition to BioInc@NYMC,” said Randi Schwartz, M.B.A., interim director of BioInc@NYMC and associate dean for academic administration. “The company’s research in sustainable nutrition will supplement the innovative work already taking place at the incubator, which continues to generate new knowledge about biomedicine while serving as an economic engine for the local community.”

“We are excited and honored to join BioInc@NYMC,” said Arianne Perry, Chief Operating Officer of Four LLC. “The incubator’s best-in-class facilities and resources are already accelerating our research and development. Our product will help people live healthier, happier lives and we are thankful for the support of NYMC, Startup New York, and the Hudson Valley community in bringing our product to market.”

Four LLC will be the fourth occupant of BioInc@NYMC, joining Conversion Energy Enterprises, a corporation that develops and prototypes laser products for medical applications; MB Group USA, a supplier of products derived from rare fruits for health purposes; and MOE Medical Devices LLC, a maker of cold electrical plasma therapeutics. The incubator’s convenient location, with its proximity to New York City, allows NYMC to go beyond providing start-ups with affordable space, giving them access to invaluable resources, such as cutting-edge core facilities and collaboration with scientists and clinicians.

A top regional economic priority from 2011 to 2013, BioInc@NYMC is a public-private enterprise, combining resources from the federal government, New York State, Westchester County and NYMC, and is the only incubator of its kind in the region that is directly co-located with a health science's university campus. It has been approved by Start-Up NY and has received the multi-year Mid-Hudson Innovation Hot Spot award granted by the New York State Regional Economic Development Council.

BioInc@NYMC occupies a 10,000 square-foot wing of a 129,000 square-foot campus building. An initial build-out of 4,500 square feet with finished laboratories, offices and shared infrastructure is ready for immediate occupancy. Development of the remaining space is planned to proceed as the initial spaces are filled. Additional available space in the same building (50,000-60,000 square feet) is ideal for future growth of the incubator or related biomedical research activities.

About New York Medical College
Founded in 1860, NYMC is one of the oldest and largest health sciences universities in the country with more than 1,400 students, 1,300 residents and clinical fellows, nearly 3,000 faculty members, and 15,000 living alumni. The College, which joined the Touro College and University System in 2011, is located in Westchester County, New York, and offers advanced degrees from the School of Medicine, the Graduate School of Basic Medical Sciences, and the School of Health Sciences and Practice. The College manages more than $36 million in research and other sponsored programs, notably in the areas of cancer, cardiovascular disease, infectious diseases, kidney disease, the neurosciences, disaster medicine, and vaccine development.

With a network of affiliated hospitals that includes large urban medical centers, small suburban clinics and high-tech regional tertiary care facilities, NYMC provides a wide variety of clinical training opportunities throughout the tri-state region for medical students, residents, and other health providers.

New York Medical College Announces First Incubator Tenants

January 15, 2015

BioInc@NYMC is the only incubator of its kind in the region that is located on a medical school campus 

Valhalla, N.Y. – January 15, 2015 – New York Medical College (NYMC) today announced the first three tenants of its recently launched biotechnology incubator, BioInc@NYMC in keeping with its mission to find new ways to prevent and treat human disease and disability, Conversion Energy Enterprises (CEE), a corporation that develops and prototypes laser products for medical applications; MB Group USA, a supplier of products derived from rare fruits for health purposes; and MOE Medical Devices, LLC, a maker of cold electrical plasma therapeutics applied and were selected to be the first occupants of BioInc@NYMC, which was officially launched on October 29, 2014.

BioInc@NYMC occupies a 10,000 square-foot wing of a 129,000 square-foot campus building. An initial build-out of 4,500 square feet with finished laboratories, offices and shared infrastructure is ready for immediate occupancy.  Development of the remaining space is planned to proceed as the initial spaces are filled. Additional available space in the same building (50,000-60,000 square feet) is ideal for future growth of the incubator or related biomedical research activities.

“Our first three tenants demonstrate that the promise of the incubator is being fulfilled: BioInc@NYMC is simultaneously generating and disseminating new knowledge about biomedicine while serving as a job creation engine and a source for Westchester's economic development,” said Edward C. Halperin, M.D., M.A., chancellor and chief executive officer. 

“We are delighted to welcome our first tenants to BioInc@NYMC. CEE, MB Group USA and MOE Medical Devices, will truly bring our facility to life. It is our hope that BioInc@NYMC tenants will take full advantage of the incubator’s state-of-the-art resources and the campus’s prime location, with its proximity to New York City and access to NYMC services. These companies have already achieved great success and we look forward to seeing them continue to flourish in their new home,” said Randi Schwartz, M.B.A., interim director of BioInc@NYMC and associate dean for academic administration.

CEE produces pre-clinical systems and tissue adhesives based on its exclusive laser technology and light activated bio-adhesives. The company continues to commercialize its technology and introduce new products into the marketplace, providing innovative healing applications that are reliable and effective. In the near future, CEE hopes to expand facilities and staff to continue generating compelling products and data.

“Conversion Energy Enterprises is excited to be one of the first tenants at BioInc@NYMC,” said Barbara A. Soltz, CEO of CEE. “Working in an energetic, intellectually supportive environment that fosters innovation and development will help us to continue the work that we do and bring our company to the next level. We look forward to working alongside fellow entrepreneurs with similar goals and aspirations, and are grateful to New York Medical College for this opportunity.”

MB Group USA produces MiraBurst™ and MiraSweet™ products for chemotherapy cancer patients; diabetics seeking to regulate blood sugar; and health conscious people seeking to cut down on sugar, MiraBurst™ products temporarily alter the taste buds so that sour and acidic foods taste sweet and MiraSweet™ is an all-natural, zero calorie sugar substitute. 

“We’re thrilled with the opportunity to leverage the intellectual collaboration at a medical school renown for ground-breaking medical and scientific advances. We look forward to continuing our work and clinical research in such an innovative environment as BioInc@NYMC,” said Emmanuel Assare, M.D., CEO of MiraBurst™. 

MOE Medical Devices, LLC develops cold electrical plasma systems and therapeutics that have the potential to provide targeted destruction of pathogens and abnormal tissues while avoiding damage to surrounding, healthy tissue. MOE is currently running several clinical trials and pre-clinical studies with promising initial results for the treatment of onychomycosis – a fungal infection of the toenails or fingernails – and intraepithelial neoplasia, which are pre-cancerous lesions found in many areas of the body, including on the skin, gastrointestinal tract, reproductive organs, and oral cavity.

“MOE Medical Devices is thrilled to join the growing number of startups at the BioInc@NYMC and the larger New York Medical College community. Our vision is to build interdisciplinary collaborations among clinicians and engineers to enable creation of innovative energy-based therapeutics for difficult-to-treat conditions. We look forward to expanding our partnership and activities with the entire NYMC community.” said Marc Zemel, CEO of MOE Medical Devices.

A top regional economic priority in 2011, 2012 and 2013, BioInc@NYMC is a public-private enterprise, combining resources from the federal government, New York State, Westchester County and NYMC, and is the only incubator of its kind in the region that is directly co-located with a health science's university campus. BioInc@NYMC has been approved by Start-Up NY and has received the multi-year Mid-Hudson Innovation Hot Spot award granted by the New York State Regional Economic Development Council (REDC).

About New York Medical College
Founded in 1860, NYMC is one of the oldest and largest health sciences universities in the country with more than 1,400 students, 1,300 residents and clinical fellows, nearly 3,000 faculty members, and 15,000 living alumni. The College, which joined the Touro College and University System in 2011, is located in Westchester County, New York, and offers advanced degrees from the School of Medicine, the Graduate School of Basic Medical Sciences, and the School of Health Sciences and Practice. The College manages more than $36 million in research and other sponsored programs, notably in the areas of cancer, cardiovascular disease, infectious diseases, kidney disease, the neurosciences, disaster medicine, and vaccine development.

With a network of affiliated hospitals that includes large urban medical centers, small suburban clinics and high-tech regional tertiary care facilities, NYMC provides a wide variety of clinical training opportunities throughout the tri-state region for medical students, residents, and other health providers.

New York Medical College Biotech Incubator Receives Innovation Spot Award

December 12, 2014

BioInc@NYMC funded to help improve New York’s competitiveness in growing new technology based companies 

Valhalla, N.Y. – December 12, 2014 – BioInc@NYMC, the new biotech incubator at New York Medical College (NYMC), has received the multi-year Mid-Hudson Innovation Hot Spot award granted by the New York State Regional Economic Development Council (REDC). NYMC has partnered with other entities in the region to provide a variety of services through its partners, but will focus on the diverse needs of the fast-growing biotechnology and life sciences industries in the Mid-Hudson region. Five regions across the State were awarded funding to launch Innovation Hot Spot programs. A new facet of the REDC initiative that was introduced last year by Governor Andrew Cuomo, the Innovation Hot Spots Competition is designed to make New York State a leader in growing new technology based companies by attracting venture capital and industry-sponsored research spending. The Hot Spots will foster innovation by offering start-ups valuable business support services to help commercialize academic research and promote further collaboration between business and academia.

“This announcement caps off an exciting week for BioInc@NYMC,” said Chancellor Edward C. Halperin, M.D., M.A. “Earlier this week, the incubator was named a tax-free zone in the Empire State Development’s START-UP NY business development initiative. This designation, coupled with the financial support that the Innovation Host Spot Award will allow us to grow and enhance BioInc@NYMC. We thank the New York State Regional Economic Development Council for this honor.” 

“Coming in close succession, these two NY State awards position our new biotech incubator at the heart of a region-wide effort to grow an innovative and job-creating biotech corridor right here in the Hudson Valley” said Robert W. Amler, M.D., M.B.A., vice president for government affairs and dean of the School of Health Sciences and Practice quote. “The award follows our incubator's designation, in two consecutive years, as the region’s top economic development priority And we especially congratulate Les Neumann, CEO of iCanNY, our partner in this award.”

“These funds will help to nurture innovation at BioInc@NYMC by offering critical business support services, further promoting research and collaboration among our tenants and academic community,” said Randi Schwartz, M.B.A., interim director, BioInc@NYMC, associate dean for academic administration.

NYMC and each of the other Hot Spots will receive up to $250,000 annually in financial support from the State to expand their direct assistance to young firms, including legal, technical and business support services.

BioInc@NYMC is the Hudson Valley’s only biotechnology incubator offering shared resources, turn-key wet lab space, and sponsored professional services to promising, high-potential entrepreneurs and start-ups. An exceptional feature is the direct location on the NYMC campus, with ready access to biomedical faculty, graduate students, library facilities, and existing research in heart disease, cancer, vaccine development, disaster preparedness and medical countermeasures. In addition to providing best-in-class infrastructure and operational services, BioInc@NYMC assists its members in refining their business strategies, conserving capital, building strong teams, and achieving development and funding milestones.

About New York Medical College
Founded in 1860, NYMC is one of the oldest and largest health sciences universities in the country with more than 1,400 students, 1,300 residents and clinical fellows, nearly 3,000 faculty members, and 15,000 living alumni. The College, which joined the Touro College and University System in 2011, is located in Westchester County, New York, and offers advanced degrees from the School of Medicine, the Graduate School of Basic Medical Sciences, and the School of Health Sciences and Practice. The College manages more than $36 million in research and other sponsored programs, notably in the areas of cancer, cardiovascular disease, infectious diseases, kidney disease, the neurosciences, disaster medicine, and vaccine development.

With a network of affiliated hospitals that includes large urban medical centers, small suburban clinics and high-tech regional tertiary care facilities, NYMC provides a wide variety of clinical training opportunities throughout the tri-state region for medical students, residents, and other health providers.

New York Medical College Launches Transformative Biotechnology Incubator

October 29, 2014

BioInc@NYMC is a vibrant, intellectually supportive platform for innovation and development that encourages collaboration and synergistic relationships among entrepreneurs.

Valhalla, N.Y., October 29, 2014 —Aimed at finding new ways to prevent and treat human disease and disability, New York Medical College (NYMC) has launched a new biotechnology incubator, BioInc@NYMC.  

A transformational project for both the Hudson Valley region and New York State, BioInc@NYMC is designed to combine entrepreneurship and academia – with the support of the public sector –to improve public health, bolster the health care sector of the region’s economy and support students and other entrepreneurs. BioInc@NYMC, which is currently being considered for START-UP NY designation, will provide incubator space for entrepreneurs and allow clients access to valuable shared resources, including state-of-the art lab equipment, workforce training suites and more. Designated a top regional economic priority in 2011, 2012 and 2013, BioInc@NYMC is a public-private enterprise, combining resources from the federal government, New York State, Westchester County, and NYMC, and is the only incubator of its kind in the region that is directly co-located with a health science's university  campus.

In addition to NYMC direct support, New York State provided a total of $7.9 million – from Empire State Development (ESD) and from Generating Employment Through New York Science (GEN*NY*SIS). The project was designated as top priority in 2011, 2012, and 2014 by ESD’s Mid-Hudson Regional Economic Development Council (REDC). In addition, the U.S. Department of Commerce, Economic Development Administration (EDA) provided $328,000 for construction of a science-business training center, co-sponsored by the Hudson Valley Economic Development Corporation, in partnership with SUNY-Westchester Community College, Division of Continuing Education and Workforce Development.

BioInc@NYMC is a vibrant, intellectually supportive platform for innovation and development that encourages collaboration and synergistic relationships among entrepreneurs whose discoveries have the potential to save lives, promote health, and improve quality of life for millions.

“For more than a century, NYMC has brought forth innovations in biomedical science to advance health care for patients and communities,” said President Alan Kadish, M.D. “BioInc@NYMC is the latest milestone in that tradition. We invite the brightest innovators to join us in the quest for better health for all.”

“The  incubator is located in a building with an honorable history which portends well for the future,” said NYMC's Chancellor Edward C. Halperin, M.D., M.A. “It was built by the late Dr. Ernst Wynder whose investigations were among the first to link smoking and lung cancer. We look forward to the commercialization of biotechnology emerging from this building to benefit the public.”

“BioInc@NYMC is the product of a great collaborative team, the very best minds in our region,” said Robert W. Amler, M.D., M.B.A., vice president for government affairs and dean of the School of Health Sciences and Practice. “Today the curtain rises on our collective vision for economic development based on attracting, nurturing, and growing the burgeoning biotech sector.”

“The biotechnology sector is thriving in the Hudson Valley and the opening of BioInc@NYMC affirms our region’s status as a hub for this cutting-edge industry,” said Democratic Conference Leader Andrea Stewart-Cousins (D/I/WF - 35th District). “I supported New York Medical College’s vision for a biotech incubator from the very beginning because I knew it represented enormous potential for job-creation and innovation right here in Westchester’s backyard. This is a very proud day for New York Medical College, and I am honored to have played a role in seeing it come to fruition.”

Assemblyman Tom Abinanti (D-Greenburgh/Mt. Pleasant) said, “This collaboration of biotechs with academics will produce not just a better local economy but better science for medical care. Centered at a health science’s university in a vibrant community—part of an exciting metropolitan area—only enhances its attractiveness.”

"I’m very pleased that BioInc@NYMC will be providing both business training and state-of-the-art research facilities for new growth companies,” said Assemblyman David Buchwald (D-White Plains). “I majored in physics in college, and I continue to view my work as a New York State Assemblyman through a scientific lens. New York Medical College has set a high standard in providing a comprehensive education to emerging medical and healthcare professionals for more than 154 years, and I believe BioInc@NYMC is a good investment for New York to create jobs and spur the economy here in the lower Hudson Valley.”       

"I am pleased to be a part of the launch of BioInc@NYMC.  It represents one of the best examples of collaboration between the public and private sectors,” said Assemblymember Shelley Mayer.  “I congratulate BioInc@NYMC and New York Medical College, and look forward to working with them as they grow and contribute to fighting disease and growing the regional economy."   

"Congratulations to Biolnc@NYMC and New York Medical College for this great new partnership, which leverages public resources to spur private innovations in science, technology and health care,” said Assemblyman Steven Otis (D-Rye). “This is another example of the state Regional Economic Development Council program creating jobs and innovation here and around the state."

In recognition of this milestone event, NYMC today also co-sponsored the Entrepreneur’s Breakfast Forum with iCAN Global. This forum is a bi-monthly business and technology summit for entrepreneurs, innovators, scientists, academics and investors. iCAN-Global is the premier virtual incubation, acceleration and commercialization network. 

About New York Medical College
Founded in 1860, NYMC is one of the oldest and largest health sciences universities in the country with more than 1,400 students, 1,300 residents and clinical fellows, nearly 3,000 faculty members, and 15,000 living alumni. The College, which joined the Touro College and University System in 2011, is located in Westchester County, New York, and offers advanced degrees from the School of Medicine, the Graduate School of Basic Medical Sciences, and the School of Health Sciences and Practice. The College manages more than $36 million in research and other sponsored programs, notably in the areas of cancer, cardiovascular disease, infectious diseases, kidney disease, the neurosciences, disaster medicine, and vaccine development.

With a network of affiliated hospitals that includes large urban medical centers, small suburban clinics and high-tech regional tertiary care facilities, NYMC provides a wide variety of clinical training opportunities throughout the tri-state region for medical students, residents, and other health providers.

-->

BioInc@NYMC Client Crave Crush Now Available Nationwide

August 17, 2017

Crave Crush helps individuals lead healthier lives by eating less sugar. The main ingredient in its patented lozenge is gymnema, a natural leaf extract that supports healthy dietary habits. 

VALHALLA, N.Y., August 17, 2017—BioInc@NYMC, New York Medical College’s biotechnology incubator, has announced its client, Crave Crush, has launched a new product, a mint lozenge that reduces sugar cravings within seconds, at The Vitamin Shoppe retail locations nationwide.

Crave Crush helps individuals lead healthier lives by eating less sugar. The main ingredient in its patented lozenge is gymnema, a natural leaf extract that supports healthy dietary habits. Gymnema influences the tongue's sweet taste receptors, thereby preventing activation of those receptors by sugar molecules and preventing those receptors from signaling the brain.

“We are pleased to see the success of Crave Crush and are excited that consumers around the country can now access a one-of-a-kind product that has the potential to change lives,” said Randi D. Schwartz, M.B.A., Director of BioInc@NYMC. “We will continue to invest in our BioInc@NYMC clients and watch as they develop from conception.”

Crave Crush is one of nine startup clients at BioInc@NYMC. As a member of NYMC’s incubator program, Crave Crush has access to invaluable resources, such as cutting-edge core facilities, wet lab space, shared resources, collaboration with scientists and clinicians, and sponsored professional services. As part of the program, BioInc@NYMC also assists its clients in refining their business strategy, conserving capital, building strong teams and achieving development and funding milestones.

“We are grateful for the ongoing support of BioInc and New York Medical College.  The state-of-the-art incubator facilities enabled us to accelerate our product development and own our research process,” said Arianne Perry, President & COO of Crave Crush LLC.

Launched in October 2014, BioInc@NYMC occupies a 10,000-square-foot wing of a 129,000-square-foot campus building. BioInc@NYMC has grown to more than 6,500-square-feet with finished laboratories, offices and shared infrastructure ready for immediate occupancy. Development of the remaining space is planned to proceed as the initial spaces are filled. Additional available space in the same building (50,000 to 60,000 square feet) is ideal for future growth of the incubator or related biomedical research activities.

About New York Medical College

Founded in 1860, NYMC is one of the oldest and largest health sciences colleges in the country with more than 1,400 students, 1,300 residents and clinical fellows, nearly 3,000 faculty members, and 19,000 living alumni. The College, which joined the Touro College and University System in 2011, is located in Westchester County, New York, and offers degrees from the School of Medicine, the Graduate School of Basic Medical Sciences, the School of Health Sciences and Practice, a School of Dental Medicine and a School of Nursing. NYMC provides a wide variety of clinical training opportunities for students, residents, and practitioners.